CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Exploring the dynamics of ctDNA following neoadjuvant therapy with CDK4/6 inhibitors combined with endocrine treatment, and its potential to guide de-escalation of adjuvant chemotherapy
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Kobieta w wieku 18-75 lat z rakiem piersi potwierdzonym w badaniu patologicznym
- •Nowotwór zależny od hormonów (dodatni na receptory estrogenowe i/lub progesteronowe) i bez zwiększenia HER2
- •Guz w stadiu wczesnym (zaawansowany lokalnie) bez przerzutów odległych
- •Dobry stan ogólny (ECOG 0-1)
- •Zgoda na udział w badaniu i testy DNA nowotworu we krwi
- •Prawidłowe funkcje wątroby, nerek i kostnego szpiku
- •Prawidłowa funkcja serca (frakcja wyrzutowa ≥55%)
- •Kobieta w wieku rozrodczym musi mieć ujemny test ciąży i stosować antykoncepcję pozahormonalną
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- July 13, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (1)
Peking University People's Hospital
Beijing, China
Trial contact
yuan peng, doctor
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.